Suppr超能文献

人卵巢癌中免疫抑制酸性蛋白的评估

Evaluation of immunosuppressive acidic protein in human ovarian cancer.

作者信息

Lin Y H, Chow S N, Chen C K, Chen R J, Huang S C, Huang G T

机构信息

Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, R.O.C.

出版信息

J Formos Med Assoc. 1994 Sep;93(9):776-80.

PMID:7735007
Abstract

This study was conducted to determine the levels of serum immunosuppressive acidic protein (IAP) in Chinese female controls and patients with ovarian tumors; and to examine the usefulness of serum IAP as an additional diagnostic test for ovarian cancer. Serum IAP was determined by a single radial immunodiffusion method. Blood samples were collected prior to surgery from patients with ovarian tumors and from female controls. A histologic diagnosis was made, and staging was performed on the basis of the FIGO staging system for ovarian cancer. The studied subjects included 33 healthy controls, 33 patients with benign ovarian tumors and 32 patients with ovarian cancer (stage I-III, and recurrent). The data were analyzed by Student's t test, Fisher's exact test and the one-way ANOVA test. The mean (+/- SD) level of serum IAP in controls was 330 +/- 61 micrograms/ml. The calculated normal upper limit (mean plus 2 SD) was 452 micrograms/ml. The mean value (867 +/- 392 micrograms/ml) in ovarian cancer was significantly higher than the controls (p < 0.001) or the benign ovarian tumors (333 +/- 95 micrograms/ml) (p < 0.001). Five (15.6%) of 32 patients with ovarian cancer had false-negative results. Three (9.1%) of 33 patients with benign ovarian tumors showed false-positive IAP levels. The pathologic diagnosis of these three patients revealed that two had endometrioma and one had mucinous cystadenoma with hemorrhagic necrosis. Three of four patients with epithelial ovarian cancer of borderline malignancy had IAP levels only slightly higher than the cut-off point of 452 micrograms/ml.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

本研究旨在测定中国女性对照者及卵巢肿瘤患者血清免疫抑制酸性蛋白(IAP)水平;并检验血清IAP作为卵巢癌辅助诊断检测手段的有效性。血清IAP采用单向免疫扩散法测定。在手术前采集卵巢肿瘤患者及女性对照者的血样。进行组织学诊断,并根据国际妇产科联盟(FIGO)卵巢癌分期系统进行分期。研究对象包括33名健康对照者、33名良性卵巢肿瘤患者和32名卵巢癌患者(I - III期及复发患者)。数据采用Student's t检验、Fisher精确检验和单因素方差分析进行分析。对照者血清IAP的平均(±标准差)水平为330±61微克/毫升。计算得出的正常上限(平均值加2个标准差)为452微克/毫升。卵巢癌患者的平均值(867±392微克/毫升)显著高于对照者(p < 0.001)或良性卵巢肿瘤患者(333±95微克/毫升)(p < 0.001)。32名卵巢癌患者中有5名(15.6%)结果为假阴性。33名良性卵巢肿瘤患者中有3名(9.1%)IAP水平呈假阳性。这三名患者的病理诊断显示,两名患有子宫内膜瘤,一名患有黏液性囊腺瘤伴出血性坏死。四名交界性恶性上皮性卵巢癌患者中有三名的IAP水平仅略高于452微克/毫升的临界值。(摘要截选至250词)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验